BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

High cholesterol / dyslipidemia clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for hypercholesterolemia: 70 (34 sponsors; 15 newly posted in the last 180 days, 2 stopped in the last 180 days; 6 new-entrant sponsors). Momentum score 32.9, rank 3 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 9, Phase 2 9, Phase 3 30, Phase 4 4, N/A 18.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Novartis Pharmaceuticals NVS13NA 5, P4 1, P3 6, P2 115
AstraZeneca AZN4P3 431
Merck Sharp & Dohme LLC MRK4P3 410
Qilu Pharmaceutical Co., Ltd.5P3 3, P1 1, P2 100
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.4P3 3, P2 100
Arrowhead Pharmaceuticals ARWR2P3 200
LIB Therapeutics LLC2P3 210
Beijing Suncadia Pharmaceuticals Co., Ltd2P2 1, P3 100
Daiichi Sankyo2P3 1, NA 100
Hasten Biopharmaceutical Co., Ltd.2P1 1, P3 100
A. Menarini International Licensing S.A. new entrant1P3 111
Hyundai Pharm1P3 100
Visirna Therapeutics HK Limited1P3 100
Eli Lilly and Company LLY4NA 1, P1 2, P2 110
Boryung Pharmaceutical Co., Ltd2NA 210
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company2NA 200
Jiangsu Hansoh Pharmaceutical Co., Ltd.2P1 210
Addpharma Inc.1P1 100
Ahn-Gook Pharmaceuticals Co.,Ltd1NA 100
Amgen AMGN new entrant1P4 110
CRISPR Therapeutics AG CRSP1P1 100
Eddingpharm (Zhuhai) Co., Ltd.1P2 100
Editas Medicine, Inc. EDIT new entrant1P2 110
ESI new entrant1NA 110
Hangzhou Dinovate Biotech Co., Ltd1P2 100

New-entrant sponsors: A. Menarini International Licensing S.A., Amgen, Editas Medicine, Inc., ESI.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-12 est.P2Shenzhen Salubris Pharmaceuticals Co., Ltd.NCT07729475 A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular EventsElevated Lipoprotein(a)not yet recruiting120
2026-12-29 est.P2Regeneron Pharmaceuticals REGNNCT07477704 A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have HypercholesterolemiaHypercholesterolemiaactive not recruiting438
2026-12-31 est.P2MediciNova MNOVNCT05464784 MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and HypertriglyceridemiaDiabetes Mellitus, Type 2; Hypertriglyceridemia; Non-Alcoholic Fatty Liver Diseaseactive not recruiting40
2027-01 est.P3A. Menarini International Licensing S.A.NCT07614958 Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Mixed Dyslipidemia; Hypercholesterolaemiarecruiting426
2027-01-04 est.P3AstraZeneca AZNNCT07000136 A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFHHeterozygous Familial Hypercholesterolaemiaactive not recruiting473

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-04 est.P3CMG Pharmaceutical Co. LtdNCT06772168 Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and DyslipidemiaDyslipidemia; Type 2 Diabetesrecruiting240
2026-11 est.P2NewAmsterdam Pharma NAMSNCT06496243 Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) LevelsDyslipidemiasrecruiting69
2026-10-04 est.P2Eddingpharm (Zhuhai) Co., Ltd.NCT07489209 A Dose-exploration Study of EDP167 in HoFHHomozygous Familial Hypercholesterolemia (HoFH)recruiting20
2026-09-03P2AstraZeneca AZNNCT07218900 A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult ParDyslipidaemiacompleted76
2026-09 est.P2Fujian Shengdi Pharmaceutical Co., Ltd.NCT07100418 A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With HyperlipidemiaHyperlipidemiaactive not recruiting224
2026-08-26P3Innovent Biologics (Suzhou) Co. Ltd.NCT07473960 IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed HyperlipidemiaNon-Familial Hypercholesterolemia and Mixed Hyperlipidemiacompleted198
2026-08-03P3Merck Sharp & Dohme LLC MRKNCT07216482 A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)Hyperlipidemiacompleted996
2026-08 est.P2Shandong Suncadia Medicine Co., Ltd.NCT07229937 A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With DyslipidemiaHyperlipidemiarecruiting189
2026-07-31 est.P1/P2Shanghai JMT-Bio Inc.NCT07140809 a Phase 1b/2a Study of JMT202 Injection in Participants With HypertriglyceridemiaHypertriglyceridemiarecruiting48
2026-07-16P3Novartis Pharmaceuticals NVSNCT04023552 Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVDCardiovascular Disease and Lipoprotein(a)completed8323
2026-07 est.P2Marea TherapeuticsNCT07199309 A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant CholesterolHypertriglyceridemiarecruiting30
2026-06-30 est.P2Shanghai Argo Biopharmaceutical Co., Ltd.NCT06497127 A Study in Patients With Mixed DyslipidemiaMixed Dyslipidemiaactive not recruiting145
2026-06-17P3Arrowhead Pharmaceuticals ARWRNCT06347016 Study of Plozasiran in Adults With Severe HypertriglyceridemiaSevere Hypertriglyceridemiacompleted311
2026-06-12P3Arrowhead Pharmaceuticals ARWRNCT06347003 Study of Plozasiran (ARO-APOC3) in Adults With Severe HypertriglyceridemiaSevere Hypertriglyceridemiacompleted446
2026-06-03 est.P1/P2Ikaria Bioscience Pty LtdNCT06471543 Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic SubjectsHypertriglyceridemia; Familial Chylomicronemia Syndromeactive not recruiting108
2026-06-01P3Arrowhead Pharmaceuticals ARWRNCT06347133 Phase 3 Study of Plozasiran in Adults With HypertriglyceridemiaHypertriglyceridemiacompleted1456
2026-06 est.P2Qilu Pharmaceutical Co., Ltd.NCT06750341 Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL CholesterolPrimary Hypercholesterolemia or Mixed Hyperlipidemianot yet recruiting156

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "hypercholesterolemia"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.